Onychomysosis - Chanpiyon Zong Pye
☆ AI Dermatology — Free Service
Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
Yon zong pye ki afekte pa Chanpiyon Zong Pye (Onychomysosis)
Trete yon moun ki gen yon enfeksyon klou chanpiyon pou dis semèn ak medikaman oral terbinafine. Remake gwoup kwasans klou ki an sante dèyè klou ki enfekte ki rete.
relevance score : -100.0%
ReferencesAntifonjik sistemik yo se tretman ki pi efikas. Meta‑analiz yo montre pousantaj gerizon mikotik jan sa a: terbinafine = 76 %, itraconazole with pulse dosing = 63 %, itraconazole with continuous dosing = 59 %, fluconazole = 48 %. Debridement klou koncomitan ogmante pousantaj gerizon. Terapi aktualite ak ciclopirox se mwens efikas; li gen yon pousantaj echèk ki depase 60 %.
Systemic antifungals are the most effective treatment. Meta-analyses shows mycotic cure rates as follows: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48%. Concomitant nail debridement further increases cure rates. Topical therapy with ciclopirox is less effective; it has a failure rate exceeding 60%.
Systemic antifungals are the most effective treatment. Meta-analyses shows mycotic cure rates as follows: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48%. Concomitant nail debridement further increases cure rates. Topical therapy with ciclopirox is less effective; it has a failure rate exceeding 60%.
Onikomikoz se yon enfeksyon chanpiyon ki afekte klou yo. Lè li koze pa dermatophytes, li rele tinea unguium. Onikomikoz gen ladan enfeksyon ki koze pa dèrmatofit, ledven, ak mwazi. Yon pwoblèm klou ki pa koze pa yon enfeksyon chanpiyon rele nail dystrophy. Malgre ke li ka afekte tou de zong men ak zong pye, onikomikoz zong pye se pi komen. Atik sa a diskite sou divès aspè onikomikoz zong pye, tankou enpak li, kalite klinik, etap, dyagnostik, ak tretman. Pandan li pa menase lavi, onikomikoz ka mennen nan konplikasyon grav tankou selulit, sepsis, enfeksyon zo, domaj tisi, ak pèt klou.
Onychomycosis is a fungal infection of the nail unit. When dermatophytes cause onychomycosis, this condition is called tinea unguium. The term onychomycosis encompasses the dermatophytes, yeasts, and saprophytic mold infections. An abnormal nail not caused by a fungal infection is a dystrophic nail. Onychomycosis can infect both fingernails and toenails, but onychomycosis of the toenail is much more prevalent. Discussed in detail in this activity are all evolving facets of the topic, including disease burden, clinical types, staging, diagnosis, and management of toenail onychomycosis. While non-life-threatening, onychomycosis can lead to severe complications such as cellulitis, sepsis, osteomyelitis, tissue damage, and nail loss.
Onychomycosis is a fungal infection of the nail unit. When dermatophytes cause onychomycosis, this condition is called tinea unguium. The term onychomycosis encompasses the dermatophytes, yeasts, and saprophytic mold infections. An abnormal nail not caused by a fungal infection is a dystrophic nail. Onychomycosis can infect both fingernails and toenails, but onychomycosis of the toenail is much more prevalent. Discussed in detail in this activity are all evolving facets of the topic, including disease burden, clinical types, staging, diagnosis, and management of toenail onychomycosis. While non-life-threatening, onychomycosis can lead to severe complications such as cellulitis, sepsis, osteomyelitis, tissue damage, and nail loss.
Terbinafine se yon medikaman ki konbat enfeksyon chanpiyon lè li bloke squalene epoxidase. Li efikas kont anpil kalite fongis po epi li apwouve pou trete chanpiyon klou lè li administre oralman. Pandan ke pifò efè segondè, tankou tèt fè mal ak pwoblèm lestomak, yo minè epi yo disparèt pou kont yo, chanjman nan gou (dysgeusia) ka varye soti nan modere a grav, pafwa mennen nan pèdi pwa. Chanjman gou ki pèmanan yo ra, men yo te rapòte.
Terbinafine is an antifungal medication that works through the inhibition of squalene epoxidase. It has activity against most dermatophytes, and it has approval for use as an oral therapy for the treatment of onychomycosis. Although most side effects are mild and self-limited, such as headache and gastrointestinal symptoms, taste disturbances (dysgeusia) can range from mild to severe, resulting in weight loss, and have rarely been reported permanent.
Terbinafine is an antifungal medication that works through the inhibition of squalene epoxidase. It has activity against most dermatophytes, and it has approval for use as an oral therapy for the treatment of onychomycosis. Although most side effects are mild and self-limited, such as headache and gastrointestinal symptoms, taste disturbances (dysgeusia) can range from mild to severe, resulting in weight loss, and have rarely been reported permanent.
Onikomikoz se yon enfeksyon chanpiyon ki afekte klou yo. Anviwon 90 % nan enfeksyon zong pye ak 75 % nan enfeksyon zong se koze pa fongis (Trichophyton mentagrophytes, Trichophyton rubrum). Sentòm yo enkli dekolorasyon klou, epesman, separasyon ak kabann klou a, ak twòp kwasans. Tretman anjeneral enplike medikaman oral tankou terbinafine oswa itraconazole, epi tretman topik se yon opsyon pou ka ki modere.
Onychomycosis is a fungal infection of the nail unit. Approximately 90% of toenail and 75% of fingernail onychomycosis are caused by dermatophytes, notably Trichophyton mentagrophytes and Trichophyton rubrum. Clinical manifestations include discoloration of the nail, subungual hyperkeratosis, onycholysis, and onychauxis. Currently, oral terbinafine is the treatment of choice, followed by oral itraconazole. In general, topical monotherapy can be considered for mild to moderate onychomycosis.
Onychomycosis is a fungal infection of the nail unit. Approximately 90% of toenail and 75% of fingernail onychomycosis are caused by dermatophytes, notably Trichophyton mentagrophytes and Trichophyton rubrum. Clinical manifestations include discoloration of the nail, subungual hyperkeratosis, onycholysis, and onychauxis. Currently, oral terbinafine is the treatment of choice, followed by oral itraconazole. In general, topical monotherapy can be considered for mild to moderate onychomycosis.
Medikaman antifonjik terbinafine ki pran oralman parèt pi efikas, men li asosye ak efè segondè sou fwa.
Chanpiyon zong pye (onychomysosis) rive nan apeprè 10 % popilasyon adilt lan, epi moun ki pi gran yo afekte pi souvan. Gason yo afekte pi souvan pase fi. Chanpiyon zong pye (onychomysosis) reprezante apeprè mwatye nan maladi klou, sa ki vle di ke defòmasyon nan zong pye yo ka soti tou nan lòt kòz pase onikomikoz.
○ Tretman – Medikaman OTC
Li difisil pou trete onychomycosis ak medikaman topik paske dwòg yo difisil pou penetre zong epè.
#Ketoconazole
#Clotrimazole
#Miconazole
#Terbinafine
#Butenafine [Lotrimin]
#Tolnaftate
○ Tretman
Tretman alontèm anjeneral obligatwa jiskaske zong ki enfekte a konplètman grandi soti.
#Terbinafine (oral)
#Itraconazole
#Efinaconazole lacquer [Jublia]
#Ciclopirox lacquer